Dimerix: Advancing new drug therapies through the clinic for unmet medical needs




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Dimerix: Advancing new drug therapies through the clinic for unmet medical needs
Released on: December 09, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dimerix Limited is a clinical stage, biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB).
  • Summary
  • Participants
  • Company
Dimerix Limited is a clinical stage, biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB). The Company is focused on developing new therapeutics discovered using its proprietary drug development platform, Receptor-Heteromer Investigation Technology (HIT).
Kathy Harrison, CEO
Dimerix Limited is a clinical stage, biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB). The Company is focused on developing new therapeutics discovered using its proprietary drug development platform, Receptor-Heteromer Investigation Technology (HIT). Our lead therapy DMX-200 is currently in Phase II clinical trials for chronic kidney disease and has received US Orphan Drug Designation for Focal Segmental Glomerulosclerosis (FSGS).